FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

l	OIVIB APPROVAL								
	OMB Number:	3235-0287							
l	Estimated average burde	en							
l	hours per response:	0.5							

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Bollag Daniel M						2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [ OCUL ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owne  Officer (give title Other (spec		
(Last) (First) (Middle) C/O OCULAR THERAPEUTIX, INC. 15 CROSBY DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 01/02/2019							below)		below)  Affairs & Quality	
(Street) BEDFORD MA 01730  (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							dividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person			
		Ta	ble I - Non-De	rivativ	ve Se	curities	s Ac	quired, D	isposed (	of, or Be	neficiall	/ Owned			
Date				Date Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		e, Transaction Disposed O Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amour Securities Beneficia Owned For	s F llly ( ollowing (	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)		(111341.4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	11(3)	
Stock Option (Right to Buy)	\$4.1	01/02/2019		A		180,000		(1)	01/01/2029	Common Stock	180,000	\$0	180,000	D	

## **Explanation of Responses:**

 $1. \ Vests \ over four \ years, \ vesting \ 1/48 \ monthly \ beginning \ on \ the \ one-month \ anniversary \ of \ the \ date \ of \ grant.$ 

/s/ Donald Notman, as

Attorney-in-Fact for Daniel M. 01/04/2019

**Bollag** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.